Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidate Contrave(TM) and its effect on markers of cardiovascular disease (visceral fat, serum cholesterol, and triglycerides) and insulin-resistance. The findings come from additional analyses of the Phase IIb multi-center clinical trial of Contrave. The data will be presented on Saturday, June 23rd, 6:00-7:15 pm and Monday, June 25th, 2007 at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and Naltrexone Improves Markers of Insulin-Resistance."

Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel formulation of naltrexone SR in a single tri-layer tablet. In a Phase IIb multi-center clinical trial, Contrave demonstrated statistically significant weight loss at 24 weeks compared to bupropion SR alone, naltrexone IR (immediate release) alone, and placebo. Contrave is now being studied in two separate multi-center Phase III studies, one of which is designed to further assess its safety and efficacy in obese subjects with Type II diabetes.

About Orexigen Therapeutics

Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take ad
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:5/16/2008)...l Mechanism May Offer Novel Approach to Blood ...EANS, May 16 /- Pharmacopei...d development of novel small,molecule therapeutics...s,Dual Acting Receptor Antagonist (DARA), showed s... in a Phase 2a study in patients with mild to,mode...
(Date:5/15/2008)... 15 /- Patients with breast or,colore...s, can expect,further treatment advances with Avas...) following new data that is being presented at th...) annual meeting in Chicago at,the end of May. Aro... which,is the premier event for cancer therapy wor...
(Date:5/15/2008)...t ASCO Showed Acceptable Tolerability Profile, ...pathy, WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ ...ulin mesylate (E7389) demonstrated activity in a,h... advanced or metastatic,breast cancer, according t...l. The study also suggests that eribulin mesylate ...
(Date:5/15/2008)...emonstrated in Blacks, Hispanics/Latinos, People ...s, PARSIPPANY, N.J., May 15 /- Daiic...ed at the American Society of,Hypertension,s Twent...ew,Orleans demonstrated that the powerful combinat...omil) safely and effectively helped,patients acros...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Media Invitation Annual General and Special Meeting of Shareholders of Haemacure 16206 1Media Invitation Annual General and Special Meeting of Shareholders of Haemacure 16206 2Navigenics 28TM 29 Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 1702 1Navigenics 28TM 29 Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 1702 2Molecular Vision and Acrongenomics Unable to Reach Agreement on the Acquisition of Molecular Vision 4447 1Study Shows the Personal Touch Is Key to Maintaining Weight Loss 16201 1Study Shows the Personal Touch Is Key to Maintaining Weight Loss 16201 2
(Date:5/16/2008)...delines quickly disseminated to community physicia...thDay News) -- Partnerships between major academic...k and effective way to spread cancer treatment adv...in Philadelphia. , Most new cancer treatments a...er care is provided at community hospitals, noted ...
(Date:5/16/2008)...in some early stage cases makes therapy of little ...ay 16 (HealthDay News) -- Colon cancer patients wi...receive chemotherapy. In fact, not only does chemo... actually harm them, a new study found. , "If yo...hen you should not be treated with chemotherapy. S...
(Date:5/16/2008)...a., May 16 /PRNewswire-USNewswire/ -- The Centers ...gency for Toxic Substances and,Disease Registry (A...,Health Improvement Award for 2008. Since its 1999... Stockpile (DSNS) in the CDC Coordinating Office,f...with LMI,s Health,Systems Management group, supple...
(Date:5/16/2008)... scheduled for Pittsburgh Zoo & PPG Aquarium for M...r Life, the Medicare product,of UPMC Health Plan, ...ual,National Senior Health & Fitness Day, which ha....", National Senior Health & Fitness Day is sched...will serve as host for three events in,Pennsylvani...
Breaking Medicine News(10 mins):Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2Health News:UPMC for Life is Pennsylvania Sponsor for National Senior Health & Fitness Day 2
...l Medicine journal, Obese or overweight Chinese in...veloping tuberculosis than those at a normal weigh...rty and undernutrition in both developed and devel...s an increasing problem that is associated with a ...
...s selective serotonin reuptake inhibitors may be a...lder men and women. Selective serotonin reuptake ...the protein that transports serotonin, a neurotran...n. This protein has recently been discovered in b...
...on shows that the work intended for global health .... The research was conducted by a UW team includin...pian, professor in the School of Public Health and..., co-director of the Global Washington Initiative;...
...n does not affect infants health. The babies deliv...quently early in life according to a new study. T...y, Hong Kong researchers found that babies deliver... rates of hospitalization or outpatient visits dur...
Other Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Antidepressents may Lower Bone Density in Older People 2Health News:Antidepressents may Lower Bone Density in Older People 3Health News:Global Health Enriching the States Economy 2Health News:C- Section Does Not Affect an Infants Health 2
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
The Guidant Flextend lead is a steroid-eluting, transvenous pace/sense lead with an extendable/retractable active-fixation helix. The extendable/retractable helix design offers various lead placement
The Vitatron Impulse II lead series are silicon rubber endocardial leads specifically designed to extend the longevity of the pacemaker system by providing energy efficient pacing. The high impedance
The RZ is a small lead body profile implantable unipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model).
Medicine Products: